Výsledky vyhledávání - "Nimali Withana"

368 CF33-CD19t oncolytic virus (onCARlytics) targets hepatocellular carcinoma (HCC) and in combination with Artemis® CD19 T cells results in significant tumor killing

Autor: Isabel Monroy, Anthony Park, Colin Cook, Guangyan Xiong, Vivien Chan, Cheng Liu, Saul Priceman, Monil Shah, Nimali Withana, Leslie Chong, Yuman Fong

Publikováno v: Regular and Young Investigator Award Abstracts.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c71d249ba3a85a26a2eb86768b4427d3
https://doi.org/10.1136/jitc-2022-sitc2022.0368

Zobrazit plný text záznamu

847 CF33-CD19t oncolytic virus (onCARlytics) in combination with off-the-shelf allogeneic CyCART-19 T cells targeting de novo CD19+ solid tumors

Autor: Anthony Park, Isabel Monroy, Colin Cook, Shuyang He, Kathy Karasiewicz, Monil Shah, Nimali Withana, Leslie Chong, Robert Hariri, Yuman Fong, Saul Priceman

Publikováno v: Regular and Young Investigator Award Abstracts.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59397c6d35155cb99c8950f8bf514101
https://doi.org/10.1136/jitc-2022-sitc2022.0847

Zobrazit plný text záznamu

nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment

Autor: Timothy Jay Price, Leslie Mi Ok Chong, Nicholas Ede, Bonnie Nixon, Nimali Withana, Sharon Yavrom, Giovanni Selvaggi, Anthony J. Good

Publikováno v: Journal of Clinical Oncology. 41:TPS481-TPS481

TPS481 Background: HER-Vaxx is a B-cell peptide vaccine composed of a fusion of 3 epitopes from the extracellular domain of HER2/neu conjugated to CRM197 with the adjuvant Montanide. Results from a phase 1b study revealed that active immunization wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1cbd4557948c8b7fb6a4934c2ed9409c
https://doi.org/10.1200/jco.2023.41.4_suppl.tps481

Zobrazit plný text záznamu

Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)

Autor: Delphine Loirat, Adam Harris, Peter Savas, Suwen Li, Matthew Wongchenko, Valentina Boni, Nimali Withana, Marie Paule Sablin, Peter Schmid, Antoine Italiano, Stina M. Singel, Enrique Espinosa, Shane White, Aruna Mani

Publikováno v: Cancer Research. 79:CT049-CT049

Purpose: Recent randomized trials in advanced TNBC have demonstrated improved efficacy with the addition of atezo to 1L nab-PAC in patients (pts) with PD-L1+ tumors (IMpassion130 [Schmid 2018]), and with the addition of the oral AKT inhibitor IPAT to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::48b47947554b84d4b0940aa51bfeec4b
https://doi.org/10.1158/1538-7445.am2019-ct049

Zobrazit plný text záznamu

Lymphoid and fibroblastic cell lineages from radiosensitive cancer patients: molecular analysis of DNA double strand break repair by major non-homologous end-joining sub-pathways

Autor: Michael J, McKay, Nimali, Withana, Deborah S, Davey, Danial, Bishop, Michael, Chao, Carl N, Sprung

Publikováno v: Asia-Pacific journal of clinical oncology. 7(1)

Radiation therapy (RT) is used in the treatment of approximately half of all cancer patients. Although there have been great improvements in tumor localization and the technical accuracy of RT delivery, some RT patients still have idiosyncratic hyper

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::36a6e56462dae61e04923ed5b5ffd60c
https://pubmed.ncbi.nlm.nih.gov/21332647

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání